SCHEMBL4120791

SCHEMBL4120791

CCCCOC(=O)c1ccc(-c2ccc(/C=C3/SC(Nc4ccc(CC(=O)O)c(F)c4)=NC3=O)cc2)cc1

nearest known ligand 0.40

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
ALOX5 P09917 13/20 0.40
HPGD P15428 1/20 0.37
RECQL P46063 1/20 0.37
PKM P14618 2/20 0.36
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
NPC1 O15118 1/20 0.36
ALDH1A1 P00352 1/20 0.36
MAPT P10636 1/20 0.36
RAB9A P51151 1/20 0.36
PDE4B Q07343 1/20 0.36
PDE4D Q08499 1/20 0.36
SLC2A1 P11166 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4120795 1.00 ALOX5 (0.40) ALOX5HPGDRECQLPKMMEN1
SCHEMBL4140602 0.73 AKR1B1 (0.40) ALOX5MEN1KMT2ANPC1ALDH1A1
SCHEMBL4137911 0.73 KMT2A (0.52) ALOX5HPGDRECQLMEN1KMT2A
SCHEMBL4122907 0.72 HDAC4 (0.41) ALOX5
SCHEMBL4140928 0.72 PDE4B (0.41) ALOX5HPGDRECQLMEN1KMT2A
SCHEMBL4140926 0.72 PDE4B (0.41) ALOX5HPGDRECQLMEN1KMT2A
SCHEMBL4140438 0.72 PDE4B (0.42) ALOX5HPGDMEN1KMT2APDE4B
SCHEMBL4143236 0.70 PRMT5 (0.37) ALOX5HPGDPKMMEN1KMT2A
SCHEMBL4143240 0.70 PRMT5 (0.37) ALOX5HPGDPKMMEN1KMT2A
Acetic Acid SCHEMBL4127823 0.70 ALOX5 (0.40) ALOX5MEN1KMT2AALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090088432-A1 Thiazolinones and Oxazolinones and their Use as Ptp1b Inhibitors TORRENT PHARMACEUTICALS LIMITED (IN) 2009-04-02 US claimed
EP-1934192-A1 THIAZOLINONES AND OXAZOLINONES AND THEIR USE AS PTP1B INHIBITORS Torrent Pharmaceuticals Ltd (IN) 2008-06-25 EP claimed
WO-2007032028-A1 THIAZOLINONES AND OXAZOLINONES AND THEIR USE AS PTP1B INHIBITORS TORRENT PHARMACEUTICALS LTD. (IN) 2007-03-22 WO claimed
US-20090088432-A1 Thiazolinones and Oxazolinones and their Use as Ptp1b Inhibitors TORRENT PHARMACEUTICALS LIMITED (IN) 2009-04-02 US disclosed
EP-1934192-A1 THIAZOLINONES AND OXAZOLINONES AND THEIR USE AS PTP1B INHIBITORS Torrent Pharmaceuticals Ltd (IN) 2008-06-25 EP disclosed
WO-2007032028-A1 THIAZOLINONES AND OXAZOLINONES AND THEIR USE AS PTP1B INHIBITORS TORRENT PHARMACEUTICALS LTD. (IN) 2007-03-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090088432-A1 Thiazolinones and Oxazolinones and their Use as Ptp1b Inhibitors PTPRF, PTPA, PTPRJ ALOX5 3505/4885HPGD 2231/4885RECQL 1687/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.